Detalles de la búsqueda
1.
Dose-Blinded Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Outcomes Through 32 Weeks.
Circulation
; 147(11): 850-863, 2023 03 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-36335531
2.
Study design and rationale of VALOR-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy who are eligible for septal reduction therapy.
Am Heart J
; 239: 80-89, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34038706
3.
Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease.
N Engl J Med
; 376(20): 1933-1942, 2017 05 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-28514624
4.
Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial.
Am Heart J
; 170(6): 1061-9, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26678626
5.
Inhibition of delta-protein kinase C by delcasertib as an adjunct to primary percutaneous coronary intervention for acute anterior ST-segment elevation myocardial infarction: results of the PROTECTION AMI Randomized Controlled Trial.
Eur Heart J
; 35(37): 2516-23, 2014 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-24796339
6.
Comparative Effects of Low-Dose Rosuvastatin, Placebo, and Dietary Supplements on Lipids and Inflammatory Biomarkers.
J Am Coll Cardiol
; 81(1): 1-12, 2023 01 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36351465
7.
Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 56 Results From the VALOR-HCM Randomized Clinical Trial.
JAMA Cardiol
; 8(10): 968-977, 2023 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37639243
8.
Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy.
J Am Coll Cardiol
; 80(2): 95-108, 2022 07 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-35798455
9.
Design Features and Rationale of the BEAR-MOON (Bridge-Enhanced ACL Restoration Multicenter Orthopaedic Outcomes Network) Randomized Clinical Trial.
Orthop J Sports Med
; 10(1): 23259671211065447, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-35097143
10.
Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.
JAMA
; 306(19): 2099-109, 2011 Nov 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-22089718
11.
Effect of C-Reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients With High-Risk Vascular Disease: A Prespecified Secondary Analysis of the ACCELERATE Trial.
JAMA Cardiol
; 5(10): 1136-1143, 2020 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32639518
12.
Effect of CETP inhibition with evacetrapib in patients with diabetes mellitus enrolled in the ACCELERATE trial.
BMJ Open Diabetes Res Care
; 8(1)2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32179516
13.
Impact of Baseline Glycemic Control on Residual Cardiovascular Risk in Patients With Diabetes Mellitus and High-Risk Vascular Disease Treated With Statin Therapy.
J Am Heart Assoc
; 9(1): e014328, 2020 01 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31852422
14.
Baseline fasting plasma insulin levels predict risk for major adverse cardiovascular events among patients with diabetes and high-risk vascular disease: Insights from the ACCELERATE trial.
Diab Vasc Dis Res
; 16(2): 171-177, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31014095
15.
Plasma Aldosterone Levels Are Not Associated With Cardiovascular Events Among Patients With High-Risk Vascular Disease: Insights From the ACCELERATE Trial.
J Am Heart Assoc
; 8(23): e013790, 2019 12 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31752637
16.
ADCY9 Genetic Variants and Cardiovascular Outcomes With Evacetrapib in Patients With High-Risk Vascular Disease: A Nested Case-Control Study.
JAMA Cardiol
; 3(5): 401-408, 2018 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29525816
17.
Prognostic value of myeloperoxidase in patients with chest pain.
N Engl J Med
; 349(17): 1595-604, 2003 Oct 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-14573731
18.
Risk stratification for patients undergoing nonurgent percutaneous coronary intervention using N-terminal pro-B-type natriuretic peptide: a Clopidogrel for the Reduction of Events During Observation (CREDO) substudy.
Am Heart J
; 153(1): 36-41, 2007 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-17174634
19.
Peroxisome proliferator-activated receptor gamma agonists for the Prevention of Adverse events following percutaneous coronary Revascularization--results of the PPAR study.
Am Heart J
; 154(1): 137-43, 2007 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-17584566
20.
Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials.
JAMA
; 297(12): 1362-73, 2007 Mar 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-17384435